Biotech
Commented by Fabian Lorenz on December 8th, 2025 | 07:15 CET
RENK better than HENSOLDT? Risk at NOVO NORDISK! Billion-dollar opportunity with RZOLV Technologies!?
Is RENK's stock better than Hensoldt's? That is what analysts are saying. According to them, the transmission specialist is attractively valued at the current level. Hensoldt, on the other hand, is having problems converting its order backlog into revenue growth, leading to a significant reduction in its price target. In contrast, RZOLV Technologies shares have enormous upside potential. The Company aims to replace a toxic chemical used in gold extraction, thereby opening up a billion-dollar market. Development is nearly complete, and patents have been filed. In just a few months, RZOLV could become a hot takeover candidate. Meanwhile, takeovers currently appear to be a way for Novo Nordisk to replenish its drug pipeline, with the Danish company taking risks worth billions - Pfizer, take note.
Read
Commented by Fabian Lorenz on December 3rd, 2025 | 10:20 CET
US government strengthens Bayer! Almonty next? What is Novo Nordisk doing?
A bombshell at Bayer: The US government has officially sided with the Company. If the Supreme Court follows the recommendation, the Leverkusen-based company could largely put the glyphosate issue behind it as early as next year. Investors and analysts are enthusiastic. Almonty Industries is also in intensive discussions with the US government. CEO Lewis Black emphasized this in an interview with Fox Business. The Company plans to start mining tungsten, which is critical for defense and aerospace, among other things, in the US as early as next year. Since 2015, the US has been 100% dependent on imports. Analysts see 40% upside potential. Novo Nordisk shares are currently looking for a bottom. To reduce its dependence on Ozempic, the Danes have concluded a billion-dollar deal.
Read
Commented by Armin Schulz on December 2nd, 2025 | 07:00 CET
The demographic clock is ticking: How Bayer, Vidac Pharma, and Novo Nordisk are positioning themselves in the billion-dollar battle for our health
The demographic clock is ticking inexorably. An aging society brings with it a flood of widespread diseases such as heart disease, cancer, and diabetes. Each one is a billion-dollar market that is pushing healthcare systems to their limits. As costs explode, brutal, cut-throat competition is emerging. The winner will not be the one with the most pills, but the one with the most effective solutions to the greatest medical and economic challenges of our time. Today, we take a look at how Bayer, Vidac Pharma, and Novo Nordisk plan to shape the future.
Read
Commented by André Will-Laudien on November 27th, 2025 | 07:55 CET
Black Friday: DAX explodes, and biotech is back in vogue: Watch out for 100% gains at Bayer, Vidac Pharma, and Novo Nordisk
The stock market has managed to break out of its consolidation phase, and the upward trend is continuing toward the end of the year. There are signs of hope for the Leverkusen-based pharmaceutical company Bayer, and Vidac Pharma is moving into the primary segment of the Düsseldorf over-the-counter market. The well-known Novo Nordisk, whose share price has been destroyed, is experiencing its fourth sell-off in three months. Some analysts are now turning positive. Investors should now be aware that prices in the biotech sector have fallen so low that even minor news items are enough to cause prices to skyrocket. Especially during the year-end portfolio adjustments, prices often reach absurd levels. We help you navigate the thicket of valuations.
Read
Commented by André Will-Laudien on November 18th, 2025 | 07:25 CET
Nvidia figures ahead, AI correction looming? Doubling alternatives include Planethic Group, Bayer, Eli Lilly, and Novo Nordisk
It does not always have to be Nvidia! If the current level of risk on the NASDAQ feels a bit too high, investors should take a look at some European gems. There may be less AI involved here, but people still work for people. This is particularly interesting as Elon Musk aims to equip the core zone of human interaction with humanoid robots, from cooking together in the kitchen to family life, which could receive "digital offspring" as early as 2027. Because the planet will soon face food and water shortages due to permanent overheating, we are taking a closer look at completely analog topics such as alternative nutrition and the prevention of obesity. This is certainly too boring for the disciples of the digital apocalypse, but it offers plenty of charm for non-digital investors.
Read
Commented by Carsten Mainitz on November 18th, 2025 | 07:10 CET
Takeover fever! LAURION Mineral Exploration, Evotec, and Mutares are tempting investors to get on board!
M&A – mergers and acquisitions - remain powerful performance drivers for shareholders of potential takeover targets. But companies that acquire others also benefit from increased growth, access to new markets and technologies, and cost synergies. According to a recent study by Bain & Company, the majority of M&A activity in the current year, amounting to around USD 265 billion, has taken place in the energy and commodities sectors. In healthcare and life sciences, deals with a volume of USD 107 billion were recorded. So who could the next takeover candidates be?
Read
Commented by Armin Schulz on November 18th, 2025 | 07:05 CET
Patents, potential, takeover candidate? Making money with less risk: The secret of BioNxt Solutions
In the high-risk world of biotechnology, the path from the laboratory to an approved drug is often an ordeal. Canadian company BioNxt Solutions may have found the key to a less painful path. Instead of developing expensive and uncertain new active ingredients, the Company refines proven drugs with innovative administration technology. The past few months have brought a remarkable series of successes that not only confirm the technology but also significantly increase the strategic value of the Company. For investors, this could be a rare opportunity.
Read
Commented by Fabian Lorenz on November 17th, 2025 | 07:10 CET
Out of BioNTech? Into Evotec and Vidac shares? What is going on with Johnson & Johnson?
Big news in biotech: Pfizer is selling its entire stake in German biotech champion BioNTech. Should investors consider doing the same? Meanwhile, Vidac Pharma is providing more and more reasons for a price explosion. The Company is developing a novel cancer therapy and has received approval to begin phase 2 clinical trials in Germany. It is also reportedly in talks with Johnson & Johnson. Might the pharmaceutical giant even make a move? Evotec, on the other hand, has recently sent mixed signals. Another milestone payment is ringing the cash register, and insider transactions are drawing attention. Yet the stock is trading at a multi-year low.
Read
Commented by Armin Schulz on November 14th, 2025 | 07:20 CET
Cancer will become curable - and these stocks could then be priceless: Evotec, Vidac Pharma, and Bayer
Cancer remains one of the greatest medical challenges of our time - but at the same time, it is creating business opportunities worth billions. The oncology market is literally exploding with annual growth of 10.8%, driven by aging societies and groundbreaking therapeutic approaches. Artificial intelligence is revolutionizing diagnostics, personalized medicine is making previously incurable tumors treatable, and digital platforms are dramatically accelerating drug development. While patients benefit from tailored treatments, investors sense big business opportunities. Today, we analyze Evotec, Vidac Pharma, and Bayer for their positioning in this future market.
Read
Commented by André Will-Laudien on November 13th, 2025 | 07:20 CET
Record stock market! And the momentum continues with Palantir, D-Wave, Gerresheimer, and NetraMark
Artificial intelligence (AI) is fundamentally changing drug development by analyzing vast amounts of data in record time and controlling clinical trials more precisely. Advanced systems identify promising drug candidates and predict therapeutic success with impressive accuracy. Companies such as NetraMark are already successfully using these technologies to accelerate development processes. At the same time, the well-known AI stars Palantir and D-Wave are driving the next wave of innovation as pacemakers in data analysis and quantum computing, recording extraordinary share price gains. The German Gerresheimer Group is also increasingly integrating AI-supported solutions into the manufacture of pharmaceutical packaging and medical technology. For investors, this represents a pool of opportunities, but the choice remains difficult!
Read